[go: up one dir, main page]

MX2020011868A - Inhibidores de los receptores erbb. - Google Patents

Inhibidores de los receptores erbb.

Info

Publication number
MX2020011868A
MX2020011868A MX2020011868A MX2020011868A MX2020011868A MX 2020011868 A MX2020011868 A MX 2020011868A MX 2020011868 A MX2020011868 A MX 2020011868A MX 2020011868 A MX2020011868 A MX 2020011868A MX 2020011868 A MX2020011868 A MX 2020011868A
Authority
MX
Mexico
Prior art keywords
receptor inhibitors
erbb receptor
erbb
compounds
her2
Prior art date
Application number
MX2020011868A
Other languages
English (en)
Inventor
Jiabing Wang
Zhenfan Yang
Qingbei Zeng
Xiaolin Zhang
Zhengtao Li
Honchung Tsui
Wei Zhong
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2020011868A publication Critical patent/MX2020011868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revelan compuestos que inhiben ErbB (por ejemplo HER2), sales farmacéuticamente aceptables, hidratos, solvatos o estereoisómeros de los mismos, y composiciones farmacéuticas que comprenden los compuestos. El compuesto y la composición farmacéutica pueden tratar efectivamente las enfermedades asociadas con los ErbB (especialmente, HER2), incluyendo cáncer.
MX2020011868A 2018-05-08 2019-05-08 Inhibidores de los receptores erbb. MX2020011868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018085998 2018-05-08
PCT/CN2019/085949 WO2019214634A1 (en) 2018-05-08 2019-05-08 Erbb receptor inhibitors

Publications (1)

Publication Number Publication Date
MX2020011868A true MX2020011868A (es) 2021-02-26

Family

ID=68467752

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011868A MX2020011868A (es) 2018-05-08 2019-05-08 Inhibidores de los receptores erbb.
MX2023008954A MX2023008954A (es) 2018-05-08 2020-11-06 Inhibidores de los receptores erbb.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008954A MX2023008954A (es) 2018-05-08 2020-11-06 Inhibidores de los receptores erbb.

Country Status (15)

Country Link
US (2) US10822334B2 (es)
EP (2) EP3814341B1 (es)
JP (2) JP7540953B2 (es)
KR (1) KR102806778B1 (es)
CN (4) CN111587248A (es)
AR (1) AR117424A1 (es)
AU (1) AU2019267959B2 (es)
BR (1) BR112020022829A2 (es)
CA (1) CA3099315A1 (es)
DK (1) DK3814341T3 (es)
ES (1) ES2977196T3 (es)
MX (2) MX2020011868A (es)
PT (1) PT3814341T (es)
TW (2) TWI811358B (es)
WO (1) WO2019214634A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
EP3778589B1 (en) * 2018-04-09 2022-05-11 Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
RS66314B1 (sr) * 2018-09-18 2025-01-31 Hoffmann La Roche Derivati hinazolina kao antitumorski agensi
UY38540A (es) * 2019-01-14 2020-08-31 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
TWI879751B (zh) * 2020-03-23 2025-04-11 印度商皮埃企業有限公司 3-被取代的苯基脒化合物及其製備和用途
EP4225300A4 (en) * 2020-10-05 2024-12-18 Dana-Farber Cancer Institute, Inc. Potent and selective inhibitors of her2
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
CN119317625A (zh) * 2021-10-20 2025-01-14 豪夫迈·罗氏有限公司 喹唑啉衍生物的结晶形式、其制备、组合物和用途
CN114262327B (zh) * 2021-12-30 2023-01-03 武汉九州钰民医药科技有限公司 一种her2小分子抑制剂图卡替尼的制备工艺
CN114671867B (zh) * 2022-03-15 2023-09-19 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用
WO2024043252A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び／又は予防のための医薬品
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
CN116102491A (zh) * 2023-02-17 2023-05-12 浙江晖石药业有限公司 一种利用连续流技术进行金属催化偶联的应用
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
CN116903615A (zh) * 2023-06-21 2023-10-20 江苏丽源医药有限公司 一种妥卡替尼及其中间体的制备方法
US20250122206A1 (en) 2023-07-28 2025-04-17 Boehringer Ingelheim International Gmbh Process for the manufacture of a her2 inhibitor
WO2025051148A1 (zh) * 2023-09-05 2025-03-13 北京鞍石生物科技股份有限公司 含氮杂芳基化合物及其制备方法和应用
CN117658818B (zh) * 2023-11-03 2025-02-07 江西巍华化学有限公司 一种4-氟-3-硝基三氟甲苯的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
WO2003040108A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
DE602006018331D1 (de) * 2005-09-20 2010-12-30 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
DK1971601T3 (da) * 2005-11-15 2010-02-08 Array Biopharma Inc N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑

Also Published As

Publication number Publication date
US20210009587A1 (en) 2021-01-14
CN111587248A (zh) 2020-08-25
CN111747953B (zh) 2021-05-07
TWI858848B (zh) 2024-10-11
US20200317669A1 (en) 2020-10-08
US11447492B2 (en) 2022-09-20
AU2019267959A1 (en) 2020-11-26
EP3814341A4 (en) 2022-01-05
AR117424A1 (es) 2021-08-04
JP7540953B2 (ja) 2024-08-27
US10822334B2 (en) 2020-11-03
MX2023008954A (es) 2023-08-18
CN112266384A (zh) 2021-01-26
ES2977196T3 (es) 2024-08-20
EP4410291A2 (en) 2024-08-07
TWI811358B (zh) 2023-08-11
AU2019267959B2 (en) 2024-06-06
WO2019214634A1 (en) 2019-11-14
DK3814341T3 (da) 2024-04-22
CA3099315A1 (en) 2019-11-14
KR20210013071A (ko) 2021-02-03
PT3814341T (pt) 2024-04-11
EP4410291A3 (en) 2024-08-14
EP3814341A1 (en) 2021-05-05
EP3814341B1 (en) 2024-03-20
JP2021523159A (ja) 2021-09-02
BR112020022829A2 (pt) 2021-02-02
TW202015690A (zh) 2020-05-01
CN111662289A (zh) 2020-09-15
CN112266384B (zh) 2022-09-23
TW202344253A (zh) 2023-11-16
CN111747953A (zh) 2020-10-09
KR102806778B1 (ko) 2025-05-12
JP2024050653A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2020007947A (es) Inhibidores de erbb/btk.
MX2019011693A (es) Compuestos que inhiben la proteina mcl-1.
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
NZ763551A (en) Compounds useful for inhibiting cdk7
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
EA202193015A1 (ru) Ингибиторы cdk
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
MX2020011542A (es) Inhibidores de cd73.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
MX2019006843A (es) Inhibidor de cdk4/6.
MX2022007626A (es) Combinaciones.
MX2022007623A (es) Combinaciones.
MX2020008076A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX379576B (es) Derivados de azetidina
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2021001925A2 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
EA202190458A1 (ru) Составы, содержащие дендример
EA202090930A1 (ru) Соединения, пригодные для ингибирования cdk7